GoodRx Holdings, Inc. (GDRX)

NASDAQ: GDRX · USD

$3.48

-0.00 (-0.1%)· Recorded snapshot

Market cap	1.2B
Revenue (ttm)	785.2M
Net income (ttm)	16.2M
EPS (ttm)	$0.05
Shares out	341.1M
P/E (trailing)	73.2x
P/E (forward)	32.1x
Volume	700,210
Beta	1.69

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 785.2M
Net income (ttm): 16.2M
EPS (ttm): $0.05
P/E (trailing): 73.2x
P/E (forward): 32.1x
Market cap: 1.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E32.1

P25 n/aP50 n/aP75 n/a

Trailing P/E73.2

P25 n/aP50 n/aP75 n/a

ROE2.5

P25 n/aP50 n/aP75 n/a

ROIC3.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GDRX indicators

Market & fundamental data

Available fields

257

Groups with data

Currency

USD

Showing 257 of 257 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001809519
Company name	GoodRx Holdings, Inc.
Country	United States
Country code	US
CUSIP number	38246G108
Earnings date	2026-11-10
Earnings time	amc
Employees	697
Employees change	-41
Employees growth	-5.56%
Enterprise value	$1.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2011
Industry	Health Information Services
IPO date	2020-09-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US38246G1085
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.2B
Market cap category	Small-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$3.48
Price currency	USD
Sector	Healthcare
SIC code	7374
Stock price date	2026-10-28
Symbol	GDRX
U.S. state	California
Website	https://www.goodrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	10.86x
Average P/E ratio (3Y)	67.32x
Earnings yield	1.37%
EV/Earnings	87.69x
EV/EBIT	15.97x
EV/EBITDA	13.1x
EV/FCF	7.23x
EV/Sales	1.81x
FCF / EV yield	13.83%
FCF yield	16.67%
Forward EV/Sales	1.76x
Forward P/E	32.13x
Forward P/S	1.46x
Graham number	1.42599
Graham upside	-58.85%
Industry forward P/E	35.4x
Lynch fair value	$0.54
Lynch upside	-84.54%
P/(FCF - SBC) ratio	9.24x
P/(OCF - SBC) ratio	8.93x
P/B ratio	1.83x
P/E ratio	73.21x
P/FCF ratio	6x
P/OCF ratio	5.86x
P/S ratio	1.51x
Price / tangible book value	63.16x
Price/EBITDA ratio	10.87x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	11.36%
EBITDA margin	13.85%
Effective tax rate	60.75%
FCF margin	25.1%
Gross margin	90.83%
Operating margin	11.36%
Pretax margin	5.27%
Profit margin	2.07%
Profit per employee	$23,313
Profitable quarters	9
Profitable years	2
Revenue per employee	$1.1M
ROA	3.05%
ROA (5Y)	2.33%
ROCE	7.53%
ROE	2.52%
ROE (5Y)	-0.33%
ROIC	3.85%
ROIC (5Y)	4.79%
SBC / revenue	8.8%
Tax / revenue	3.2%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-46.78%
EPS growth (Q)	-44.46%
EPS growth (QoQ)	484.28%
EPS growth 3Y	32.84%
EPS growth years	3
FCF growth	4.01%
FCF growth (Q)	63.59%
FCF growth (QoQ)	651.92%
FCF growth 3Y	15.92%
FCF growth 5Y	13.19%
Gross profit growth	-4.82%
Gross profit growth (Q)	-5.43%
Gross profit growth 3Y	1.74%
Gross profit growth 5Y	3.77%
Net income growth	-53.04%
Net income growth (Q)	-33.54%
Net income growth (QoQ)	630.2%
Net income growth 3Y	11.29%
Net income growth years	3
OCF growth	5.76%
OCF growth (Q)	63.03%
OCF growth (QoQ)	582.82%
OCF growth 3Y	16.42%
OCF growth 5Y	9.52%
Operating income growth	-21.41%
Operating income growth (Q)	-11.85%
Operating income growth 3Y	18.65%
Revenue growth	-1.83%
Revenue growth (Q)	-1.31%
Revenue growth (QoQ)	3.3%
Revenue growth 3Y	1.76%
Revenue growth 5Y	4.47%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-4.5M
Depreciation and amortization	$19.5M
EBIT	$89.2M
EBITDA	$108.8M
EPS	$0.05
FCF per share	$0.58
Financing cash flow	$-101M
Free cash flow	$197.1M
Free cash flow minus SBC	$128M
Gross profit	$713.2M
Income taxes	$25.1M
Investing cash flow	$-85.8M
Net borrowing	$-5M
Net cash flow	$14.8M
Net income	$16.2M
Operating cash flow minus SBC	$132.4M
Operating income	$89.2M
Revenue	$785.2M
Stock-based compensation	$69.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.24
Book value per share	$1.90
Debt / EBITDA	4.6
Debt / equity	0.83
Debt / FCF	2.73
Goodwill	$430.3M
Interest coverage	2.19
Long-term assets	$743.6M
Long-term liabilities	$537.5M
Net cash (debt)	$-242.8M
Net cash / market cap	-20.54%
Net debt / EBITDA	2.23
Net debt / equity	0.37
Net debt / FCF	1.23
Piotroski F-Score	5
Property, plant and equipment	$39.1M
Shareholders' equity	$647.6M
Tangible book value	$18.7M
Tangible book value per share	$0.06
Total assets	$2.3B
Total cash	$296.1M
Total debt	$539M
Total liabilities	$1.7B
WACC	10.25%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.43
Current assets	$1.6B
Current liabilities	$1.2B
Current ratio	1.38
Net working capital	$155.7M
Quick ratio	0.42
Working capital	$441.5M
Working capital turnover	1.82

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	9.06%
Dividend yield	0%
Shareholder yield	9.06%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.98
1D price change	-0.14%
1M price change	3.58%
1M total return	3.58%
1W price change	-1.42%
1W total return	-1.42%
1Y price change	-7.96%
1Y return CAGR	-7.96%
1Y total return	-7.96%
20-day SMA	$3.43
200-day SMA	$2.81
3M price change	13.77%
3M total return	13.77%
3Y price change	-32.09%
3Y return CAGR	-12.1%
3Y total return	-32.09%
50-day SMA	$3.43
50-day SMA vs 200-day SMA	50over200
52-week high	$3.89
52-week high date	2026-08-11
52-week low	$1.77
52-week low date	2026-03-02
5Y price change	-91.82%
5Y return CAGR	-39.39%
5Y total return	-91.82%
6M price change	52.19%
6M total return	52.19%
All-time high	$64.22
All-time high date	2020-09-29
All-time low	$1.77
All-time low date	2026-03-02
Average true range (ATR)	$0.12
Average volume	985.9K
Beta (1Y)	2.1
Beta (2Y)	1.1
Beta (5Y)	1.69
Change from 52-week high	-10.67%
Change from 52-week low	96.33%
Change from all-time high	-94.6%
Change from all-time low	96.05%
Change from open	0.43%
Day's gap	-0.57%
Dollar volume	$2.4M
High price	$3.49
Low price	$3.45
Monthly RSI	41.57
Open price	$3.46
Position in 52-week range	62.5%
Premarket change	-1.15%
Premarket close	$3.48
Premarket price	$3.44
Premarket volume	149
Previous close	$3.48
Price vs 150-day SMA	16.44%
Price vs 20-day SMA	1.28%
Price vs 200-day SMA	23.36%
Price vs 50-day SMA	1.11%
Relative volume	0.71
Return from IPO open	-92.47%
Return from IPO price	-89.5%
RSI	51.64
Sharpe ratio	0.06
Sharpe ratio (3Y)	0.03
Sharpe ratio (5Y)	-0.4
Sortino ratio	0.18
Sortino ratio (3Y)	0.14
Sortino ratio (5Y)	-0.5
Volume	700.2K
Weekly RSI	57.05
YTD price change	28.04%
YTD total return	28.04%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	93.8M
Float percentage	27.49%
Shares change (QoQ)	1.94%
Shares change (YoY)	-9.06%
Shares held by insiders	4%
Shares held by institutions	17.42%
Shares outstanding	341.1M
Short % of float	4.43%
Short % of shares	1.22%
Short ratio	4.5 days

Deeper analysis on GDRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GDRX report

Is a complete GDRX research report available?

No complete published report is available for GoodRx Holdings, Inc. (GDRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

GoodRx Holdings, Inc. (GDRX)

Price

Financial snapshot

Fair-value bridge

Latest news · GDRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GDRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GDRX

Frequently asked questions